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Abstract
Background: TRNT1 (CCA-adding transfer RNA nucleotidyl transferase) enzyme deficiency is a new metabolic
disease caused by defective post-transcriptional modification of mitochondrial and cytosolic transfer RNAs (tRNAs).
Results: We investigated four patients from two families with infantile-onset cyclical, aseptic febrile episodes with
vomiting and diarrhoea, global electrolyte imbalance during these episodes, sideroblastic anaemia, B lymphocyte
immunodeficiency, retinitis pigmentosa, hepatosplenomegaly, exocrine pancreatic insufficiency and renal tubulopathy.
Other clinical features found in children include sensorineural deafness, cerebellar atrophy, brittle hair, partial villous
atrophy and nephrocalcinosis.
Whole exome sequencing and bioinformatic filtering were utilised to identify recessive compound heterozygous
TRNT1 mutations (missense mutation c.668T>C, p.Ile223Thr and a novel splice mutation c.342+5G>T) segregating
with disease in the first family. The second family was found to have a homozygous TRNT1 mutation (c.569G>T),
p.Arg190Ile, (previously published).
We found normal mitochondrial translation products using passage matched controls and functional perturbation of 3’
CCA addition to mitochondrial tRNAs (tRNACys, tRNALeuUUR and tRNAHis) in fibroblasts from two patients, demonstrating
a pathomechanism affecting the CCA addition to mt-tRNAs. Acute management of these patients included transfusion
for anaemia, fluid and electrolyte replacement and immunoglobulin therapy. We also describe three-year follow-up
findings after treatment by bone marrow transplantation in one patient, with resolution of fever and reversal of the
abnormal metabolic profile.
Conclusions: Our report highlights that TRNT1 mutations cause a spectrum of disease ranging from a childhood-onset
complex disease with manifestations in most organs to an adult-onset isolated retinitis pigmentosa presentation.
Systematic review of all TRNT1 cases and mutations reported to date revealed a distinctive phenotypic spectrum
and metabolic and other investigative findings, which will facilitate rapid clinical recognition of future cases.
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Background
The field of monogenic mitochondrial disease has increased
exponentially since the advent of next generation sequen-
cing. Commencing with ‘targeted gene panels’ sequencing
nuclear genes encompassing the mitochondrial proteome,
moving rapidly to whole exome sequencing (WES) and
more recently whole genome sequencing, it has enabled
the diagnosis of many mitochondrial disease patients
worldwide. New syndromes have been revealed [1, 2] and
older syndromes such as Sengers syndrome have acquired
genetic redefinition [3]. One of the processes that has been
particularly associated with disease is mitochondrial transla-
tion. A number of new genetic disorders have recently been
found in this pathway [4–7] with the majority of the newly
reported cases being tRNA aminoacyl synthetase deficien-
cies. Furthermore the genetic disorders of mitochondrial
protein synthesis have been flagged as an exciting area for
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clinicians as there appear to be tissue specific diseases mak-
ing it possible to draw genotype-phenotype correlations [8].
In this study we explore a syndrome resulting from
the deficiency of TRNT1 (CCA-adding tRNA nucleotidyl
transferase enzyme), which performs an essential post-
transcriptional modification by adding on the cytosine-
cytosine-adenine (CCA) trinucleotide sequence to the 3′
end of all newly produced tRNAs. This TRNT1-
dependent tRNA modification is essential for both cyto-
solic and mitochondrial tRNAs (mt-tRNAs) to partici-
pate in protein biosynthesis. The CCA trinucleotide
sequence is required to accurately attach amino acids, to
position the tRNA on the ribosome and also to conclude
protein translation [9].
Recently, two different TRNT1 related disease entities
have been reported; a haematological description of a
congenital sideroblastic anaemia associated with immuno-
deficiency, fevers, and developmental delay (SIFD) in
childhood [10–12] and an adult presentation of retinitis
pigmentosa with a focus on ophthalmological features
[13]. In this report we describe four cases including a new
family with two severely affected children whose presenta-
tion encompassed both sets of clinical features, and in
whom we have identified a novel TRNT1 mutation. We
explored the functional significance of the TRNT1 muta-
tions in these children and found clear evidence of im-
paired post-transcriptional modification of mt-tRNAs. We
systematically review all the features reported in the cases
published thus far and study the complete clinical pheno-
type, including a metabolic description that will enable
physicians to diagnose this disease clinically and perform
targeted genetic investigations.
Methods
Patients
We report one new family and also add a metabolic con-
text to the phenotype of one previously reported family
[10, 11]. Both families attended the metabolic clinic at
our institution for diagnosis and treatment.
P1 was born to unrelated white European parents after
a normal pregnancy. She presented at 2 weeks of age
with a febrile illness associated with poor feeding and
diarrhoea. No infective cause was found and she recov-
ered from this episode. However over the next 3 years
she had multiple recurring acute systemic illnesses.
These episodes were characterised by fever, diarrhoea
and vomiting, metabolic acidosis, electrolyte imbalance
(episodic hyponatraemia, hypokalaemia, hypocalcaemia,
hypomagnesaemia and hypophosphataemia), elevated
hepatic transaminases and raised inflammatory markers.
She was investigated for an immune deficiency and
was found to have severe hypogammaglobulinaemia with
B cell maturation arrest requiring three-weekly sando-
globulin supplementation. She was also found to have a
transfusion dependent sideroblastic anaemia with vari-
able neutropaenia and thrombocytopaenia. Immuno-
logical investigations revealed low IgG, IgA and IgM
(Table 1) while blood films showed anisocytosis, neutro-
paenia, pencil cells and elliptocytes. Bone marrow exam-
ination showed that most erythroblasts had abnormal
siderosis with around 2/3 being ring or crescent forms.
Megakaryopoiesis was abundant but with dysplastic nu-
clear morphology.
She had recurrent episodes of encephalopathy associ-
ated with nystagmus and photophobia which appeared
to improve markedly with benzodiazepine therapy.
Development was globally delayed and she had retinal
dystrophy. Brain MRI was initially normal but subse-
quently progressive cerebellar atrophy was observed. In
addition, in the last stages of her disease, brain MRI
showed widespread abnormalities with multiple lesions
resembling infection. She developed recurrent bacterial
infections and gastrointestinal involvement with chronic
gastritis, partial villous atrophy, hepatosplenomegaly and
pancreatic insufficiency (undetectable stool elastase).
Biochemical investigations revealed mildly elevated
blood lactate at 2.5 mmol/L (reference range <2) and
muscle mitochondrial respiratory chain complex IV ac-
tivity at the lower end of the reference range (ratio to
citrate synthase 0.015, reference range 0.014–0.034).
Muscle histology was normal. In particular, neither
ragged-red nor cytochrome oxidase-negative fibres were
observed. She died at 3 years and 3 months following a
progressive encephalopathy.
P2 is the younger male sibling of P1 and is the older
sibling of non-identical twins (Fig. 1a). He was admitted
at 3 weeks of age with poor feeding, loose stools and pal-
lor, and again at 4 weeks with poor feeding, fever and
anaemia (haemoglobin 66 g/L). Although his blood film
showed occasional nucleated red cells with possible
sideroblastic granules, bone marrow examination at one
month showed dyserythropoeisis but no ringed sidero-
blasts. He had central hypotonia, retinal pigmentation,
hepatosplenomegaly and exocrine pancreatic insufficiency.
Immunological investigations revealed initially low B cells
which normalised and low IgG, IgA and IgM (Table 1). He
had recurrent seizures and his MRI brain at 10 months
demonstrated multiple focal lesions in the cerebral hemi-
spheres and cerebellum (Fig. 2). He died at 10 months of
age because of intractable status epilepticus.
P3 and P4, previously reported as cases 1 and 2 [10]
were born to first cousin Pakistani parents (Fig. 1d).
They had five children including a stillborn baby at
32 weeks’ gestation and two other daughters who are
well except for radioulnar fusion due to Cenani-Lenz
syndrome caused by a homozygous LRP4 mutation [14].
P3 was first diagnosed with sideroblastic anaemia at
8 months. She developed recurrent episodes of fever
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Table 1 TRNT1 deficient patients- biochemical and other laboratory data
Analyte P1 P2 P3 P4 P4: 2 years
post bone
marrow transplant
Reference
range
Plasma Lactate mmol/L >2.5 3.1 1.2–2.8 1.4–2.7 1.1 <2
CSF Lactate mmol/L 2.5 NA NA NA NA <2
CSF protein g/L 0.41–1.79 NA NA NA NA <0.3
Plasma glycine μmol/L 504 248 280–332 310–344 235 100–330
Plasma threonine μmol/L 256 305 168–266 329–556 260 70–220
Plasma proline μmol/L 246 255 291–452 304–414 249 85–290
Plasma leucine μmol/L 91 133 140–245 96–198 129 65–220
Plasma isoleucine μmol/
L
46 73 63–118 69–114 68 26–100
Plasma valine μmol/L 142 216 244–404 197–323 255 90–300
Plasma alanine μmol/L 296 458 562–875 572–665 346 150–450
Plasma ornithine μmol/L 101 107 83–210 112–241 145 25–120
White Cell Ubiquinone
pmol/mg protein
NA 57.0 10.0 NA NA 37–133
Creatine kinase u/L NA 87–383 88 41–137 NA 75–230
Electrolytes mmol/L Episodic hyponatraemia
(131), hypokalaemia (2.7),
hypocalcaemia (1.7),
hypomagnesaemia (0.51),
hypophosphataemia (0.89)
Normal Episodic hyponatraemia,
hypokalaemia, hypocalcaemia,
hypomagnesaemia,
hypophosphatemia
Not done during acute
episode of illness
Normal
Intact PTH pmol/L 3.3 NA 8.0 NA NA 1.1–5.4
Gamma GT u/L 300 normal NA NA NA 10–20
Urine organic acids Mildly raised 3OH-butyrate
with moderately raised
adipate, suberate and
3OH-sebacate and mildly
raised sebacate, C8:1
and C10:1 dicarboxylates,
3OH (C14:0, C8:1, C10:1)
dicarboxylates
No abnormality Strongly raised
3-hydroxybutyrate
and acetoacetate
Mildly raised pyruvate NA NA
Urine amino acids NA NA Generalised aminoaciduria NA NA NA
Urine NAG/creatinine 612–2606 217 666 NA NA 3.5–27.3
Urine RBP/creatinine 4531–25714 961 419 NA NA 1.9–42.6
Hb g/L Lowest 79 (freq transfusions) 66, 67 65–74 71, 68 (sample clotted) 114–145
Blood film Anisocytosis, neutropaenia,
dimorphic red cells, pencil cells,
elliptocytes on film
Marked anisopoikilocytosis
with hypochromic red cells,
elliptocytes and fragments
Marked red cell anisopoikilocytosis.
Many hypochromic, microcytic red
cells and elliptocytes. Numerous
Neutrophils show toxic
granulation marked RBC
abnormalities: poikilocytosis,
NA
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Table 1 TRNT1 deficient patients- biochemical and other laboratory data (Continued)
red cell fragments. Occasional
target cells
microcytosis, eliptocytosis,
hypochromic red cells.
polychromasia
IgG g/L 2.24–5.42
(3.7–15.8)
0.86
(3–10.9)
3.95, 10.6
(5.4–16.1)
4.11–4.32
(4.9–16.1)
10.90
IgA g/L <0.03
(0.3–1.3)
<0.06
(0.2–0.7)
0.15–0.62
(0.5–1.8)
0.17–0.41
(0.4–2.0)
0.76
IgM g/L 0.11–0.23
(0.5–2.2)
0.17
(0.6–2.1)
0.09, 0.20
(0.5–2.2)
0.29–1.19
(0.5–2.0)
0.58
Lymphocyte Subsets Absent B cells Low B cells Low B cells NA NA
Other Moderate exocrine pancreatic
insufficiency (stool elastase 182 μg/g,
normal >200); later undetectable.
Hair shafts: normal histology.
Duodenal biopsy: partial villous atrophy.
Liver iron:143 μg/100 ml dry weight.
Normal very long chain fatty acids (VLCFA)
Pancreatic elastase 1
(μg/g) <15 Undetectable
Normal ammonia,
blood spot carnitine
profile, VLCFA, copper,
caeruloplasmin, plasma
methylmalonic acid (MMA),
autoimmune profile; large
bowel histology – mild patchy
increase in eosinophils in
lamina propria
Normal transferrin
glycoforms, blood
spot carnitine profile,
VLCFA, urate, copper,
caeruloplasmin, plasma
MMA
NA
Muscle histology No ragged-red fibres
or COX negative fibres
ND NA ND NA
Muscle respiratory chain
enzymes (ratio to citrate
synthase)
Complex I 0.139
Complex II + III 0.064
Complex IV 0.015
NA Complex I 0.228
Complex II + III 0.068
Complex IV 0.007
NA NA Complex I
0.104–0.268
Complex II
and III
0.040–0.204
Complex IV
0.014–0.034
NA: not available
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from 1 year and global developmental delay, retinitis
pigmentosa and bilateral sensorineural deafness. She had
low B cells with hypogammaglobulinaemia and features
of sideroblastic anaemia on bone marrow examination.
She required numerous blood transfusions to maintain
her Hb above 70 g/L. During the febrile episodes she
developed hyponatraemia, hypokalaemia, hypocalcaemia,
hypomagnesaemia and hypophosphatemia and general-
ised aminoaciduria. Plasma amino acid analysis revealed
elevated proline 347 μmol/L (85–290), alanine 749 μmol/
L (150–450) and glutamine 1014 μmol/L (480–800). Urine
organic acids showed strongly raised 3-hydroxybutyrate
and acetoacetate. Urate was mildly raised and red cell nu-
cleotide profile showed the presence of some abnormal
nucleotides. At four years, she was found to have a
urate renal calculus which resulted in right sided
hydronephrosis. Porphyria screen and sequencing of
exons 9 and 11 of the mevalonate kinase gene (per-
formed because of the recurrent fevers) were normal.
Muscle biopsy demonstrated markedly reduced com-
plex IV activity expressed as a ratio to citrate synthase
at 0.007 (0.014–0.034) (Table 1). She died after multi-
organ failure and presumed cephalosporin-induced
toxic epidermal necrolysis at 14 years.
Her younger brother P4 had global developmental delay
and hypotonia with a microcytic anaemia. He presented at
two months with high fever, vomiting and diarrhoea. An-
aemia (haemoglobin 71 g/L) and panhypogammaglobuli-
naemia were noted (Table 1). His blood film showed
slightly immature neutrophils with toxic granulation and
marked red cell abnormalities including poikilocytosis,
microcytosis, elliptocytosis, hypochromic red cells and
polychromasia, similar to the findings in his sister P3. He
had fever recurring every 7–10 days, which was associated
with vomiting and diarrhoea. Urine organic acids revealed
mildly raised pyruvate. Pearson syndrome was excluded in
both P3 and P4 by screening for mitochondrial DNA dele-
tions. P4 underwent bone marrow transplantation (BMT)
after which his fevers resolved, his growth improved and
he made some developmental progress. He remains sys-
temically well 3 years post BMT. At 10.5 years of age he
has started to walk independently and is making progress
with speech, but continues to have moderate hearing loss
and retinopathy.
Whole exome sequencing
Genetic investigations were performed with ethical ap-
proval from the National Research Ethics Committee
Fig. 1 a Pedigree of family of P1 and P2. b Bioinformatic analysis of whole exome data. c Sanger sequencing results showing that P1 and P2 were
compound heterozygous for the TRNT1 mutations. d Pedigree of family of P3 and P4. e Linkage mapping data showing sizes of the chromosomal
regions with the highest LOD scores. f Electropherogram demonstrating the TRNT1 mutation in P3 and P4 (c.569G>T p.Arg190Ile) [11]
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London Bloomsbury, UK and informed consent was ob-
tained from parents for investigations and publication of
findings. Whole exome sequencing (WES) was per-
formed in P1 and P2 using the Agilent SureSelect cap-
ture kit and Illumina’s HiSeq 2000 high throughput
sequencing. Raw fastq files were aligned to the hg19
reference genome using novoalign version 2.08.03. We
processed 2600 in-house control samples together with
these samples to create gVCF files using the Haplotype
Caller module of the Genome Analysis Tool Kit (GATK)
version 3.1.1. These individual gVCF files were pooled
into combined gVCF of 100 samples, and used for vari-
ant calling (Genotype gVCF module of GATK 3.1.1).
Variant quality scores were re-calibrated according to
GATK recommendations for indels and SNPs. Rare vari-
ants (defined as an allele frequency <0.5 % in our in-
house control samples) which were splicing, nonsynon-
ymous, frameshift or presumed loss-of-function and
present in both P3 and P4 were prioritised. In view of
non-consanguinity, compound heterozygous inheritance
was assumed.
Homozygosity mapping
Whole genome-wide SNP genotyping was performed in
P3 and P4, their parents and one unaffected sibling
using the Illumina HumanCytoSNP-12 microarray. LOD
scores were calculated as published before [15]. All pro-
cessing was carried out in accordance with the Infinium
HD Ultra Assay protocol (Rev B, 2010, Illumina Inc, San
Diego, USA). Data were initially analysed assuming an
autosomal recessive model using the Illumina Genome
Studio software which generates genotypes, copy num-
ber and loss of heterozygosity data (cnvPartition v3.1.6,
Illumina). Quality control checks were performed to as-
sess data quality. Samples were assessed for their call
rate which should be >98 and >99 % average across the
batch. The B-allele frequency plots and copy number
analysis results were checked to identify potentially con-
taminated samples.
Sanger sequencing of mutations
All exons and exon-intron boundaries of candidate
genes located within homozygous intervals in P3 and P4
were amplified (GoTaq PCR Kit Promega) according to
the manufacturer’s protocol and Sanger sequenced. The
TRNT1 mutations identified by WES in P1 and P2
were also confirmed by Sanger sequencing, using
primer sequences for TRNT1 exons 3 and 6 (exon 3:
Fig. 2 Axial (a) and Coronal (b) T2-weighted images and Sagittal
(c) Post-contrast T1 weighted images of the brain MRI in P2,
showing multiple focal lesions in the cerebral hemispheres and
cerebellum involving both grey and white matter with contrast
enhancement. Bilateral subdural collections were also present
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Forward ATAGCAGGAGGAGCAGTGAG and reverse
GACTGCAGGGTTTATGACGG and exon 6 forward
CAGATTTTGCTTGTGATATGCCA and reverse ACCC
CATAACCCAAACTTTGTC) All PCR products were se-
quenced using the Big Dye Terminator Reaction Kit on a
2400GeneAmp® 9700 sequencer. Sequencing data were
analysed using the Sequencher v. 5.2.4 software.
Western blot
Western blot was performed as described previously
[16] using OXPHOS antibody cocktail (Abcam) in P1
and P2 compared to controls. Fibroblast cells were not
available for P3 and P4.
Mitochondrial translation assay
Patient and control fibroblasts were plated on 6-well
plates. At 80 % confluence, they were washed twice with
methionine and cysteine-free DMEM (1 mL/well of a 6
well plate). Labelling medium (600 μL) was added to
each well and incubated for 20 min at 37 °C, before add-
ing emetine (SIGMA, 25 mg/ml in PBS) to a final con-
centration of 100 μg/mL with a further incubation at
37 °C for 30 min. 100 μCi L-[35S]-methionine (Perkin
Elmer - NEG009L005MC) was then added to each well
to a final concentration of 166.6 μCi/mL per well and
incubated for 30 min at 37 °C. The cells were washed
with PBS and trypsinised, protein was isolated and con-
centration determined using BCA assay, and western
blot was performed. The gel was stained with Simply-
Blue SafeStain (Thermo Fisher Scientific), dried at 80 °C
under vacuum for 1 h and exposed to a phosphorimage
screen for 72 h.
Analysis of mitochondrial tRNA CCA sequences by
circularisation reverse transcription–PCR assay
Circularisation reverse transcription PCR (cRT–PCR)
and sequencing were used to determine both 5’ and 3’
ends of mt-tRNA as described previously [17]. Briefly,
2.5 μg of total RNA was circularized with T4 RNA ligase
(New England Biolabs) in the presence of DNase I
(Roche) followed by phenol–chloroform extraction and
ethanol precipitation. Reverse transcription was carried
out using Omniscript Reverse Transcriptase (Qiagen)
with a gene-specific reverse primer (tRNA_His_R1).
Newly synthesized cDNA was used as a template for a
PCR reaction, primed with R1 primer and a forward primer,
F1. The region amplified contained the junction of the 5’
and 3’ extremities. Products were cloned using TOPO TA
Cloning Kit (Life Technologies) and sequenced. The follow-
ing primers were used in the analysis: tRNA_His_Reverse:
CAATCTGATGTTTTGGTTAAACTATA, tRNA_His_For
ward: AATCTGACAACAGAGGCTTACGACCC, tRNA_-
SerAGY_Reverse: CATGAGTTAGCAGTTCTTGTGAGC
TT, tRNA_SerAGY_Forward: CCCCATGTCTAACAACA
TGGCTTTC, tRNA_Cys_Reverse: TGCAATTCAATATG
AAAATCACCTCG and tRNA_Cys_Forward: TTCGAA-
GAAGCAGCTTCAAACCTGCC. The following TOPO
clones were sequenced: (a) mt-tRNAHis C1 29 clones, P1 32
clones, P2 29 clones (b) mt-tRNACys 16 clones for C1, P1
and P2 (c) mt-tRNASerAGY C1 13 clones, P1 16 clones, P2
15 clones.
Northern blotting
Northern blot analysis was performed as described
previously [18]. Briefly, total RNA was isolated from
primary skin fibroblasts using TRIzol® LS Reagent (Life
Technologies) according to the manufacturer’s instruc-
tions. RNA was resolved by Urea-PAGE on a 10 % gel,
transferred to a nylon membrane, UV-crosslinked to the
membrane and hybridised with radioactively labelled T7-
transcribed RNA probes.
Protein modelling
The molecular graphics program MOE (Molecular
Operating Environment, 2012) running on an Ubuntu
Linux workstation was used to visualize, mutate and
analyse the crystal structure of full-length human mito-
chondrial CCA-adding enzyme [19] solved at a reso-
lution of 1.9A.
Identification of other cases
A PubMed search was performed using the
terms TRNT1’, ‘SIFD’ and ‘sideroblastic anaemia’. Since
the gene TRNT1 was only associated with human dis-
ease in 2014 we searched for publications from 2014 to
date. Only papers reporting cases with confirmed
TRNT1 mutations were included.
Results
Genetic findings
Exome sequencing
Only four genes (CEL, SLC12A1, SRRM, TRNT1) contain-
ing compound heterozygous mutations shared between
the affected siblings P1 and P2, were found after bioinfor-
matic filtering (Fig. 1b). Of these, TRNT1 appeared the
most likely causative gene given the clinical history.
We identified a novel splice mutation c.342+5G>T to-
gether with a known pathogenic missense mutation,
c.668T>C p.Ile223Thr. Parents were each heterozy-
gous for one mutation, confirming segregation with
disease in this family (Fig. 1c).
Homozygosity mapping
Homozygosity mapping was performed prior to the
advent of WES in P3, P4, parents and an unaffected sib-
ling. The mapping revealed 7 significant homozygous re-
gions shared between the two affected siblings spanning
a total of 56.8 megabases, including four regions with a
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LOD score of 1.93 (Fig. 1e) containing 716 genes includ-
ing 11 genes with a Maestro (predicted mitochondrial
localisation) score >10 (TRNT1, GRPEL1, LONP1, NDUFA
11, CLPP, TIMM44, NDUFA7, ATP6V1E1, SLC25A1, TXN
RD2 and CHCHD10). The TRNT1 mutation illustrated in
Fig. 1f (c.569G>T, p. Arg190Ile) in this family has previously
been published by another group [11] who were also inves-
tigating this family, unbeknown to us.
Western blot
Immunoblotting showed no decrease in the steady-state
levels of either mtDNA or nuclear encoded OXPHOS
subunits in the patients (P1 and P2) when compared
with controls.
Mitochondrial translation and analysis of CCA addition to
mitochondrial tRNAs
The mitochondrial translation rate in the TRNT1 defi-
cient patients (P1 and P2) was within the range detected
in passage matched healthy and non-mitochondrial dis-
ease controls (Fig. 3a). We sought to determine if the
identified TRNT1 mutations result in diminished CCA
addition to mitochondrial tRNAs (mt-tRNAs). To this
end we performed high resolution northern blotting of
total RNA isolated from P1 and P2 primary fibroblasts.
This analysis suggested partial lack of CCA in mt-
tRNACys (P1: 5 %, P2: 5 %, C1: <1 %, C2: <1 %) and mt-
tRNALeuUUR(P1: 2 %, P2: 2 %, C1: <1 %), when compared
to controls. However, we detected no obvious differences
in CCA addition for other mt-tRNAs tested, including
mt-tRNAIle, -His, -Arg, -Pro, -Phe, -Ser(AGY) (Fig. 3b). In order
to uncover more subtle differences in maturation of the
3’ end of mt-tRNA, potentially beyond Northern blotting
detection limits, we analysed the ends of mt-tRNA after
circularisation, reverse transcription, PCR amplification
and cloning (cRT–PCR). The cRT-PCR analysis of
mttRNASerAGY and mt-tRNACys was consistent with the
high resolution northern blotting analysis where we
found a proportion of incorrectly processed mt-tRNACys
(Fig. 3). Also in agreement with northern blots, we did
not find any defects in maturation of mt-tRNASerAGY in
this additional cRT-PCR. In addition this method also
detected a proportion of incorrectly processed mt-
tRNAHis (Fig. 3c). Taken together these data indicate
that TRNT1 mutations lead to defective CCA addition
to mt-tRNAs.
Fig. 3 a Upper: Mitochondrial translation assay in disease control (DC) and patient (P1 and P2) fibroblasts. Coomassie blue (below) used as a
loading control. The mitochondrial translation products are indicated on the left: four subunits of complex I (ND), one subunit of complex III (cyt
b), three subunits of complex IV (CO) and two subunits of complex V (ATP). Lower: western blot for OXPHOS proteins in patients P1 and P2
compared to controls. The OXPHOS subunits detected are shown to the left with their respective complexes in parentheses. b High-resolution
Northern blot analysis of total RNA isolated from the TRNT1 deficient patient or control primary fibroblasts. The blots were probed with the
mt-tRNA-specific RNA probes as indicated. Full-length mt-tRNAs are indicated as + CCA (“0” on the scale). Mt-tRNAs lacking CCA are highlighted
by “-CCA” (“-3” on the scale next to each blot). c The results of cRT-PCR analysis for mt-tRNAHis, mt-tRNASer and mt-tRNACys in control and TRNT1
deficient patients. The following number of clones were analysed for each sample: C1: 29, P2: 27, P1: 25
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Analysis of all reported patients
Initial presentation
Together with the patients in this report, we analysed
clinical features in 18 subjects reported to date. There
appears to be a spectrum of disease ranging from a
neonatal-onset disease to an adult presentation. The
earliest presentation was within 3 h of birth with pallor
and splenomegaly. Of the 18 cases described to date, in-
cluding the 4 patients in this report, more than half (10/
18, 55 %) presented in the first 2 months of life (range
1 day-19 years). The most striking initial feature (9/18,
50 %) was a systemic ‘inflammatory’ illness where an
infective aetiology was not identified. The febrile illness
was accompanied by gastrointestinal upset such as poor
feeding, diarrhoea (8/18, 44 %) and vomiting (7/18,
39 %). In one adult case [13] a febrile illness was re-
corded in childhood, which was thought to be due to ju-
venile rheumatoid arthritis, and in one paediatric case
[12] lactic acidosis and vomiting was noted but fever
was not reported. The inflammatory episodes appeared
to wax and wane cyclically. Other first presentations in-
cluded anaemia and delayed development. The adult
cases presented between the ages of 18 and 21 years
with impaired vision. Table 2 demonstrates key clinical
features and laboratory findings in all patients.
Blood and immune system
Sideroblastic anaemia (13/18, 72 %) is a very significant
feature of the clinical syndrome. In the majority of cases
it was observed during investigation of unexplained fe-
brile illness. Interestingly the three adult cases had an
asymptomatic microcytosis with a haemoglobin often in
the lower end of the reference range (~130 g/L), con-
trasting with the paediatric cases who had severe an-
aemia (Hb range 48–82 g/L). One child appeared to
have a predominantly neurological phenotype with no
febrile episodes or sideroblastic anaemia [12]. Overall 16
(89 %) cases had evidence of anaemia (mild in the adult
cases) with microcytosis (median Hb 72 g/L, median
MCV 63.4 fl). The majority of cases (12/18, 67 %) also
had B cell lymphopaenia with or without an accompany-
ing hypogammaglobulinaemia. Only two cases had a low
total white cell count.
Retinitis pigmentosa
Of the four cases followed at our institution, one had
retinal dystrophy and two other cases developed pig-
mentary retinopathy. Overall six cases (33 %) had
pigmentary retinopathy, of which three were adults. In
the adult patients this was the only discernible symp-
tomatic feature. Although largely asymptomatic in
childhood, one adult patient reported a history of
night blindness as a child.
Neurological phenotype and neuroimaging
Most patients (14/18, 78 %) had developmental
delay, which was global except in one case reported
to have isolated motor delay. Sensorineural deafness
was reported in 7/18 (39 %) cases. Seven patients
developed seizures, six patients had ataxia and five
patients were hypotonic. Two of our cases (P1 and
P2) developed episodes of encephalopathy. Only one
patient was reported to have ptosis and ophthalmo-
plegia. Four patients had cerebral atrophy, two were
noted to have brainstem changes, one had thalamic
changes and two had cerebellar changes (atrophy in
one, cerebellar hypoperfusion in the other) on neu-
roimaging. Two of our cases (P1 and P2) also had
multiple cerebral and cerebellar focal lesions which
resembled infection (Fig. 2).
Table 2 Clinical features of TRNT1 deficiency
Clinical feature Total Percent
Symptom/sign
Recurrent ‘inflammatory’ episodes 14/18 78
Developmental delay 14/18 78
Sideroblastic anaemia 13/18 72
Diarrhoea 8/18 44
Vomiting 7/18 39
Sensorineural deafness 7/18 39
Seizures 7/18 39
Retinitis pigmentosa 6/18 33
Splenomegaly 6/18 31
Ataxia 5/18 28
Brittle hair 5/18 28
Hypotonia 5/18 28
Nephrocalcinosis 5/18 28
Renal tubulopathy 4/18 22
Hepatomegaly 4/18 22
Pancreatic insufficiency 3/18 17
Villous atrophy 2/18 11
Acute encephalopathy 2/18 11
Cardiomyopathy 1/18 6
Laboratory investigations
Low or low-normal haemoglobin 16/18 89
Microcytosis 16/18 89
B lymphopaenia/hypogammaglobulinaemia 12/18 67
Anisocytosis 9/18 50
High lactate 6/18 33
Metabolic acidosis 5/18 28
High alanine 3/18 17
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Kidney, liver and spleen involvement
Six patients (33 %) had splenomegaly. Five patients had
nephrocalcinosis (28 %) and four (22 %) had hepatomeg-
aly. One of the cases followed at our institution (P3) de-
veloped a urate renal calculus.
Gastrointestinal
In addition to some patients developing cyclical vomit-
ing and diarrhoea accompanying the febrile illness, three
cases had pancreatic insufficiency and two had partial
villous atrophy on duodenal biopsy.
Cardiomyopathy
Only one case was reported to have (dilated)
cardiomyopathy.
Additional features
Brittle hair was noted in five cases.
Survival
Median age of death was 37.5 months (range
10 months - 14 years). The three adult patients were
alive and systemically well at 18, 19 and 21 years. Two
patients [10] underwent myeloablative allogenic bone
marrow transplant (BMT). Both were alive 3 years
post BMT with no recurrence of periodic fever.
Metabolic and biochemical testing
Analysis of findings in all cases revealed that an ele-
vated lactate was recorded in six cases, associated with
metabolic acidosis in five cases, elevated plasma ala-
nine in three cases and evidence of renal tubulopathy
in four cases.
We performed detailed metabolic investigations in the
patients seen at our institution (Table 1). Blood lactate
was mildly elevated in all four subjects (P1-P4) in the
current study, ranging from 2.4–3.1 mmol/L (reference
range <2). Plasma alanine was elevated in three subjects
(patient range 458–875; reference range 150–450 μmol/
L) and proline was elevated in two subjects (patient
range 304–452; reference range 85–290 μmol/L). Plasma
threonine was high in all patients (patient range 256–
556; reference range 70–220 μmol/L) and plasma glycine
was raised in three cases (patient range 332–504; refer-
ence range 100–330 μmol/L). Branched chain amino
acids and ornithine were elevated in P3 and P4. Interest-
ingly P4 had a normal amino acid profile post bone
marrow transplant.
Electrolyte abnormalities in P1 and P3 observed dur-
ing acute inflammatory episodes included hyponatrae-
mia, hypokalaemia, hypocalcaemia, hypomagnesaemia
and hypophosphataemia. Renal tubular dysfunction was
documented in 3 patients (P1, P2 and P3; not done in
P4), with high urinary N-acetyl-beta-D-glucosaminidase
(NAG):creatinine and retinol binding protein (RBP):crea-
tinine ratios. In P1 elevated hepatic transaminases were
a persistent feature.
Muscle respiratory chain enzymes
Muscle respiratory chain enzymes (RCEs) were mea-
sured in two of the four patients (P1 and P3) described
here in detail. P3 had definitively low complex IV of
0.007, 30 % of control mean (reference range 0.014-
0.034) whereas P1 had a value at the lower end of the
reference range (0.015), which was disproportionately
low compared to complexes I-III (Table 1). In one pa-
tient (N) reported previously complex IV was affected in
muscle (0.25, control range 0.58–2.5) and liver (0.25,
control range 0.6–2.5) while complex II + III 0.06 (0.5–
1.9) and complex I + III 0.15 (0.58–2.5) were also low in
muscle [12].
Genotypes and protein modelling of mutations
All TRNT1 mutations published to date are shown in
Fig. 4a and all reported missense mutations are modelled
in silico in Fig. 4b. The homozygous p.Arg190Ile substi-
tution harboured by P3 and P4 is predicted to cause a
severe conformational protein change when the hydro-
gen bond network formed by arginine is broken by iso-
leucine, leaving the protein either unfolded, or folded
but dysfunctional (Fig. 3c).
One of the mutations found in P1 and P2 (c.688C>T,
p.Ile223Thr) was also found in SIFD patients from eight
apparently unrelated pedigrees of white Caucasian, Afro-
Caribbean and Hispanic origins reported previously [11].
This suggests that this may be a mutational hotspot. In
silico modelling of p.Ile223Thr showed that isoleucine is
a buried amino acid and, since the substituted threonine
can also be buried satisfying its H-bond, it confers a
mild phenotype.
The adult patients had either a mononucleotide dele-
tion or insertion of an adenine at the same position
(c.1246) on one allele. These changes were located in the
last exon and predicted to result in a truncated protein.
Interestingly the deletion at c.1246 was also found in a
paediatric SIFD patient [11]. The other allele in the adult
patients contained either a deletion or splicing mutation;
the authors predicted that the deletion caused a minor
change to the protein conformation and that the splicing
was altered in a subset of transcripts [13].
Discussion
We report a new family with TRNT1 mutations, includ-
ing a novel pathogenic splicing mutation, and show that
TRNT1 mutations cause a complex multisystem disease
leading to manifestations in most organs. In this report we
used a systematic review of all previously reported cases
to characterise the phenotypic presentation of TRNT1
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deficiency, a new disorder of mitochondrial and cytoplas-
mic translation. Our in vitro studies provide evidence of
mitochondrial pathogenicity in this disease, indicating
clear functional impairment of the addition of CCA to
mt-tRNAs in patient fibroblasts, leading to defective mt-
tRNA post transcriptional modification.
From the descriptions thus far, there are two ends of the
disease spectrum: a paediatric disorder which starts early in
life with unexplained cyclical febrile episodes accompanied
by gastrointestinal upset and features of sideroblastic an-
aemia, and an adult disease with retinitis pigmentosa and
asymptomatic microcytosis [10–13]. In addition to being
almost the only sign of adult disease, retinitis pigmentosa
was also found in three paediatric patients, suggesting that
this may be a key feature of the disease which is under-
reported, since it may be undetected if patients are not
specifically screened by an experienced ophthalmologist.
Also splenomegaly, nephrocalcinosis and hepatomegaly
were reported in six, five and four cases respectively.
We highlight oxidative phosphorylation (OXPHOS)
impairment in TRNT1 deficiency, with evidence of
mitochondrial complex IV being definitively low in two
patients and at the lower end of the reference range in
one patient. It is not possible to know how many pa-
tients would display OXPHOS abnormalities in this
disease if muscle respiratory chain enzyme analyses were
performed in all patients. Given the pivotal role of
TRNT1 in mitochondrial translation, multiple RCE ab-
normalities would be expected. The observation of
mtDNA translation defects with biochemical evidence of
isolated complex IV deficiency is similar to other mito-
chondrial translation disorders (e.g., RARS2 and YARS2
deficiency) where biochemical findings ranged from nor-
mal to multiple RCE defects or isolated complex IV defi-
ciency [20, 21]. The multi-organ involvement in these
patients is perhaps unsurprising given the ubiquitous na-
ture of the TRNT1 enzyme and its key role in protein
synthesis both in cytoplasm and mitochondria. One of
Fig. 4 a Schematic diagram of the TRNT1 gene demonstrating the mutations reported to date. Mutations found in the milder adult phenotype are
shaded in blue and those found in childhood-onset severe disease are shaded in pink. b The human TRNT1 protein is shown in ribbon representation.
All missense mutations published to date are shown as space fill atoms, white for carbon, red for oxygen and blue for nitrogen. The mutant residue is
shown at each position and labelled. c Stick representation of the environment surrounding the p.Arg190Ile mutation. Carbon atoms in white, oxygen
in red and nitrogen in blue. Ile190 is shown in green throughout. Hydrogen bonds are shown as dotted lines. The extensive hydrogen bond network
stabilising the wildtype Arg190 is completely lost following mutation to the hydrophobic Ile190. d Stick representation of the environment surrounding
the p,Ile223Thr mutation. Carbon atoms in white, oxygen in red and nitrogen in blue. Wildtype Ile223 is shown in green throughout. Hydrogen bonds
are shown as dotted lines. The protein is able to accommodate the Thr223 mutation in place of the buried, hydrophobic Ile223 through the hydrogen
bond from the Thr223 sidechain
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the limitations of this study is that we have not studied
the effect of the TRNT1 mutations on cytoplasmic
tRNAs. As a dually localised enzyme, TRNT1 is respon-
sible for the maturation of both nuclear and mitochond-
rially encoded tRNAs. Whilst an affect on cytosolic
tRNA maturation cannot therefore be ruled out, we
chose to focus on defects of the mitochondrial transla-
tion system, in view of the clinical presentation of a
mitochondrial disease in our patients along with others
previously reported [12]. Primarily mitochondrial disease
presentations have been previously reported for other
dually localised enzymes such as PUS1, MTO1 and
TRIT1 [22–24], perhaps indicating a greater susceptibil-
ity of the mitochondrial translation apparatus to such
perturbations than its comparatively more robust cyto-
solic counterpart.
Variable changes were observed in the plasma amino
acid profiles of these four children with TRNT1 defi-
ciency. It is difficult to ascertain the relevance of these
findings in a small group of patients. One possible ex-
planation is that impaired muscle metabolism leads to
decreased break down of branched chain amino acids.
On the other hand the abnormalities could be related to
TRNT1 deficiency and resulting backlog from disor-
dered cellular protein translation and further studies will
be needed to establish this.
Often patients with inherited metabolic disease de-
compensate with febrile illness and metabolic physicians
are involved in the care of these patients during these
acute phases. In all four patients presented here, febrile
illness was a component of the disease rather than a pre-
cipitant and mevalonate kinase deficiency (which is char-
acterised by recurrent episodes of fever in infancy) was
excluded. TRNT1 deficiency produces a complex multi-
system disease which can be confused with overwhelming
sepsis given the febrile episodes with raised inflammatory
markers. Whereas sepsis obviously must be excluded in
the first instance, clues at this stage are the presence of
microcytic anaemia with anisocytosis and B cell lympho-
paenia, typically with hypogammaglobulinaemia.
The paediatric TRNT1 disease (SIFD) enters into the
differential diagnosis of genetic sideroblastic anaemia,
inherited immunodeficiencies and also of autoimmune
inflammatory disease. Other genetic sideroblastic anae-
mias which present similarly and may need exclusion
include Pearson syndrome (caused by mtDNA deletions)
with sideroblastic anaemia, exocrine pancreatic failure
and pancytopaenia [25]; and YARS2 and PUS1 deficiency
which cause myopathy, lactic acidosis and sideroblastic
anaemia (MLASA) syndrome [26–28]. YARS2 is specific-
ally a mitochondrial aminoacyl tRNA synthetase whereas
PUS1 has a dual subcellular location. Of the cytoplasmic
translation defects, LARS mutations have been noted to
present with a multi-system disease consisting of acute
liver failure, anaemia, renal tubulopathy, developmental
delay, seizures, failure to thrive and deterioration of liver
function with illness [29]. Cyclical fever and B cell immu-
nopathy are not features of these diseases, and so they can
be distinguished clinically from TRNT1 deficiency.
The mainstay of the acute management of these
patients consists of treatment of the episodes of in-
flammation with rehydration and electrolyte supple-
mentation and transfusion for anaemia. So far two
patients have received BMT and the results appear en-
couraging, although more long-term data are needed.
It is not known whether BMT early in the disease
course might prevent the neurodevelopmental features
of this disorder. Ideally randomised double-blinded
placebo-controlled clinical trial evidence is necessary
to draw meaningful conclusions but this is not always
possible in ultra-rare diseases [30].
TRNT1 null mutations are probably embryonically le-
thal given that siRNA knockdown of the gene led to
cytotoxicity and apoptosis [11]. Although TRNT1 func-
tions both in the cytoplasm and the mitochondrion, the
presence of syndromic manifestations typical of a mito-
chondrial disease suggests that post-transcriptional
modification of mt-tRNAs, specifically CCA addition, is
critical to disease pathogenesis. We examined the impact
of the patient mutations on tRNA modification in primary
patient fibroblast cell cultures and found mt-tRNAs par-
tially lack 3’ CCA in mt-tRNACys, mt-tRNALeuUUR and
mt-tRNAHis. While being beyond the scope of the current
study, it would be interesting to study all mt-tRNAs using
cRT-PCR in patients with different TRNT1 mutations
since our finding contrasts with the findings of a previous
study which suggested that only mt-tRNASer(AGY) was
reduced, with more profound decrease of CCA-tailed mt-
tRNASer(AGY) in a patient with the more severe clinical
phenotype [12]. We did not find a reduction in mt-
tRNASer(AGY) on Northern blot or cRT-PCR. The reasons
for these differences are not clear at present but one pos-
sible explanation is that these functional differences and
patient survival are related to the severity of the genetic
mutation. For example it could be hypothesised that the
long survival of patient 8 reported by Wiseman et al. [10]
who was homozygous for p.Ile223Thr, is explained by the
amino acid change where in silico analysis revealed a mild
conformational change in the protein. In severely affected
compound heterozygote patients with p.Ile223Thr in one
allele, the splicing mutation found in the opposing allele
may explain the severe phenotype.
Conclusion
In summary we investigated patients with a complex,
childhood-onset, multisystem disorder who fall into the
SIFD spectrum of TRNT1 disease. In addition adult on-
set retinitis pigmentosa has been reported in TRNT1
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deficiency. We demonstrate that deficiency of TRNT1
had an impact on mt-tRNA post-transcriptional modifi-
cation in affected patient cells. Systematic review of all
cases reported to date allowed us to amalgamate know-
ledge of the clinical phenotype. This will aid clinical
recognition of further cases. Early bone marrow trans-
plantation should be considered in these cases to halt
the episodic febrile and metabolic decompensations,
thereby improving quality of life.
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